Sanofi And Selecta To Partner On Immunotherapies For Life-Threatening Allergies
This article was originally published in The Pink Sheet Daily
Vaccine and immunotherapy-focused Selecta, up to now focused on grants for funding, signs its first big pharma partner around targeted, antigen-specific programs for undisclosed allergies.
You may also be interested in...
Pfizer gained an option to acquire Dutch biopharma AM-Pharma, while Lilly hooked up with Germany’s BioNTech in a cancer immunotherapy pact. Juno acquired German biotech Stage Cell Therapeutics.
Without user fee coverage, advisory committees for Merck and Stallergenes’ new era grass allergy products must be pushed back from their scheduled November dates.
Both Merck and French biotech Stallergenes have filed BLAs with FDA for approval of their respective grass allergy immunotherapies.